ABVC BioPharma (ABVC) Projected to Post Quarterly Earnings on Tuesday

ABVC BioPharma (NASDAQ:ABVC) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect ABVC BioPharma to announce earnings of ($0.40) per share and revenue of $0.1130 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 20, 2026 at 9:30 AM ET.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings data on Monday, May 18th. The company reported ($0.06) earnings per share (EPS) for the quarter.

ABVC BioPharma Stock Performance

Shares of NASDAQ ABVC opened at $0.95 on Tuesday. The business’s 50 day moving average price is $1.33 and its 200-day moving average price is $1.36. ABVC BioPharma has a fifty-two week low of $0.88 and a fifty-two week high of $3.40. The company has a market cap of $25.23 million, a price-to-earnings ratio of -2.38 and a beta of 0.57.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Investors Weigh In On ABVC BioPharma

Large investors have recently bought and sold shares of the company. Citadel Advisors LLC acquired a new stake in ABVC BioPharma during the 3rd quarter valued at approximately $48,000. Millennium Management LLC acquired a new stake in ABVC BioPharma during the third quarter valued at $60,000. Finally, Geode Capital Management LLC raised its position in shares of ABVC BioPharma by 5.8% in the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after acquiring an additional 6,017 shares during the period. Hedge funds and other institutional investors own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.